CTRI/2023/12/060661
Not yet recruiting
未知
A comparative study to evaluate the efficacy and safety of Vortioxetine and Escitalopram in patients with depression. - NI
Ronakkumar Chandubhai Patel0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: F321- Major depressive disorder, singleepisode, moderate
- Sponsor
- Ronakkumar Chandubhai Patel
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All patients giving written consent will be taken.
- •Subjects \>18 \& \<60 years of age of either gender, diagnosed to be suffering from depression as per ICD\-10 (International classification of Diseases) with or without somatic symptoms or recurrent depressive disorder as per ICD\- 10 with or without somatic symptoms, duration of current depressive episode is to be between 4 weeks to 12 months, and scoring \=7 and \= 34 on MADRS (Montgomery Asberg Depression Rating scale), 12 CGI\-S (Clinical global impression) \>2 and \<6 on the initial visit will be enrolled in the study.
Exclusion Criteria
- •Current or past comorbid diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, a psychotic disorder not otherwise specified, mood\-congruent or mood\-incongruent psychotic features, bipolar disorder, alcohol or substance\-use disorder, organic mental disorder including dementia, eating disorder, or obsessive compulsive disorder; presence of a seizure disorder; previous treatment with electroconvulsive therapy; currently pregnant/lactating women; and risk of suicide. • All patients with an unclear history of antidepressant treatment. Patients not giving informed consent. Patients scoring \=6 on MADRS items number 10 (suicidal thoughts) at screening or baseline, history of non response to an adequate (6 week) trial of three or more antidepressant (with or without mood stabilizers) during the current episode, with imminent risk of suicide or injury to self, others, or property.
- •Besides, patients with current clinically significant neurological, metabolic (including typel diabetes), hepatic, renal, hematological, pulmonary. cardiovascular, gastrointestinal, and/or urological disorder such, as unstable angina, congestive heart failure (uncontrolled), or central nervous system (CNS) infection that would pose a risk to the subject if they were to participate in the study or that might confound the results of the study subjects with human immunodeficiency virus (HIV) seropositivity (or history of seropositivity), history of malignancy, or any chronic incapacitating illness will be excluded.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 4
Efficacy of oral tranexamic acid and topical triple combination cream in treatment of melasmaHealth Condition 1: L814- Other melanin hyperpigmentationCTRI/2024/04/065382MOHAN H
Not yet recruiting
Not Applicable
Iron deficiency anemia treatment in adults: comparing daily versus alternate day iron regimensCTRI/2024/03/064861Viswanathan S
Not yet recruiting
Not Applicable
A study to compare two drugs Seratconazole versus Luliconacole for improvement of symptoms and to compare the side effectsHealth Condition 1: L089- Local infection of the skin and subcutaneous tissue, unspecifiedHealth Condition 2: L088- Other specified local infections of the skin and subcutaneous tissueCTRI/2022/10/046157Yuvarani R
Not yet recruiting
Not Applicable
Comparison study to evaluate the efficacy and safety of a topical gelCTRI/2024/08/072002Abbott India Limited
Not yet recruiting
Not Applicable
Safety and effectiveness of rosuvastatin versus rosuvastatin with fenofibrate in patients with dyslipidemia.Health Condition 1: E785- Hyperlipidemia, unspecifiedCTRI/2024/07/070696Dr Shivam Yadav